Dr. James Price

Dr. Price is an experienced clinical oncologist. He graduated from the University of Sheffield in 2009. After completing his specialty training in Nottingham in 2018, he relocated to The Christie in Manchester to pursue a fellowship in proton beam therapy. In January 2020, he was appointed to a PhD research fellowship focusing on oropharyngeal cancers (cancers of the tonsils, tongue, or throat) and became a Consultant Clinical Oncologist in May 2020. He specialises in treating head and neck cancers using advanced radiotherapy techniques, including IMRT, VMAT, and IGRT, as well as proton beam therapy (IMPT).

Dr. Price has a strong interest in research and serves as the radiotherapy quality assurance lead for the UK phase 3 TORPEdO trial (IMPT vs IMRT for reducing toxicity in oropharyngeal cancer) and the PROTIS trial (IMPT vs IMRT for treating sinonasal cancer). His other research interests include improving patient selection for (chemo)radiotherapy through mathematical models and using advanced imaging techniques to predict treatment outcomes.

Dr. Price is the clinical lead for implementing electronic patient-reported outcomes (ePROMs) across clinical teams at The Christie and serves as the medical lead for alcohol and smoking services within the Trust. Additionally, he is a Clinical and Educational supervisor for Clinical Oncology trainees and an examiner for the Royal College of Radiologists.